Fuji Pharma Co., Ltd. announced consolidated earnings results for the first half of fiscal year ending September 30, 2021. To summarize the results for the second quarter, sales in the field of women's healthcare increased YoY by JPY 370 million, or 2.2%. Steady sales in this field compensated for the impact of the coronavirus pandemic on contrast media and OLIC contract businesses. As a result, operating income increased by JPY 950 million, or 54.8%, from the previous fiscal year. Profits increased significantly in the first half of the fiscal year, but the main reason for this was the postponement of research and development expenses.